TPX2 and neoplasm: The re-expression of TPX2WT, but not TPX2K249R, facilitated the in vivo tumour growth of HepG2 xenografts with endogenous TPX2 knockdown, which was abolished by treatment with both LDHA inhibitor, GSK2837808A, and AURKA inhibitor, alisertib (Fig 5A and B).